Detalhe da pesquisa
1.
LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
Blood
; 131(15): 1730-1742, 2018 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29453291
2.
Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes.
Haematologica
; 104(6): 1156-1167, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30514804
3.
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
Proc Natl Acad Sci U S A
; 109(8): 2989-94, 2012 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-22323599
4.
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses.
Cancer Immunol Res
; 10(4): 420-436, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35181787
5.
Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup.
Bioorg Med Chem Lett
; 21(15): 4436-40, 2011 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21733693
6.
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Cancer Discov
; 9(7): 872-889, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31076479
7.
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Cancer Cell
; 28(1): 57-69, 2015 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26175415
8.
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors.
ACS Med Chem Lett
; 4(3): 358-62, 2013 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900673
9.
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
PLoS One
; 8(7): e67583, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23844038
10.
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
PLoS One
; 8(8): e72967, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24009722
11.
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Mol Cancer Ther
; 11(4): 909-20, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22389471